ES2160955T3 - Derivados del acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz. - Google Patents
Derivados del acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz.Info
- Publication number
- ES2160955T3 ES2160955T3 ES97923625T ES97923625T ES2160955T3 ES 2160955 T3 ES2160955 T3 ES 2160955T3 ES 97923625 T ES97923625 T ES 97923625T ES 97923625 T ES97923625 T ES 97923625T ES 2160955 T3 ES2160955 T3 ES 2160955T3
- Authority
- ES
- Spain
- Prior art keywords
- ilo
- rent
- phenyl
- bencilo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 4
- 229920004518 DION® Polymers 0.000 abstract 2
- DMSSTTLDFWKBSX-UHFFFAOYSA-N 1h-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N=NNC2=C1 DMSSTTLDFWKBSX-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 abstract 1
- 229950001139 timonacic Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCION SE REFIERE A INHIBIDORES DE LA METALOPROTEASA DE LA MATRIZ, A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y A UN PROCEDIMIENTO DE UTILIZACION DE LOS MISMOS PARA TRATAR DIVERSOS ESTADOS FISIOLOGICOS. LOS COMPUESTOS DE LA INVENCION PRESENTAN LA FORMULA GENERAL (I), DONDE R 1 REPRESENTA ALQUILO C 6 C 12 ; ALCOXI C 5 - C 12 ; ALQUILT IO C 5 C 12 ; UN POLIETER DE FORMULA R 2 O(C 2 H 4 O) A -, EN DONDE A ES 1 O 2; Y R 2 ES ALQU ILO C 1 - C 5 , FENILO O BENCILO; Y ALQUINILO SUSTITUIDO DE FORMULA R 3 (CH 2 ) B - C C -; EN DONDE B ES 1-10 Y R 3 ES H -, HO - O R 4 O -, EN DONDE R 4 ES ALQUILO C 1 - C 3 , FENILO O BENCILO. LAS FRACC IONES ALQUILO, FENILO Y BENCILO DE R 1 PUEDEN LLEVAR AL MENOS UN SUSTITUYENTE FARMACEUTICAMENTE ACEPTABLE. EL SUBINDICE N ES 2-4. R 5 REPRESENTA FENILO; IMIDOILO DE 4-12 ATOMOS DE CARBONO; (3H) - BENZO - 1,2,3 - TRIAZIN - 4 - ON - 3 - ILO; N - SACARINILO; (2H) - FTALACIN - 1 -ON - 2 - ILO; 2 - BENZOXAZOLIN - 2 - ON - 3 ILO; 5,5 - DIMETILOXAZOLIDINA - 2,4 -DION - 3 - ILO; Y TIAZOLIDIN 2,4 - DION - 3 - ILO; PUDIENDO LLEVAR LAS FRACCIONES FENILO Y BENZO DE R 5 AL MENOS UN SUSTITUYENTE FARMACEUTICAMENTE ACEPTABLE. SE INCLUYEN ASIMISMO LAS SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS MATERIALES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64768296A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2160955T3 true ES2160955T3 (es) | 2001-11-16 |
Family
ID=24597888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97923625T Expired - Lifetime ES2160955T3 (es) | 1996-05-15 | 1997-05-12 | Derivados del acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz. |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0923529B1 (es) |
| JP (1) | JP3354941B2 (es) |
| CN (1) | CN1225620A (es) |
| AR (1) | AR007101A1 (es) |
| AT (1) | ATE205822T1 (es) |
| AU (1) | AU727468B2 (es) |
| BR (1) | BR9709075A (es) |
| CA (1) | CA2253795C (es) |
| CO (1) | CO5011113A1 (es) |
| DE (1) | DE69706874T2 (es) |
| ES (1) | ES2160955T3 (es) |
| HR (1) | HRP970247B1 (es) |
| ID (1) | ID17326A (es) |
| MY (1) | MY116903A (es) |
| PA (1) | PA8429501A1 (es) |
| SV (1) | SV1997000033A (es) |
| TN (1) | TNSN97086A1 (es) |
| TW (1) | TW442468B (es) |
| WO (1) | WO1997043237A1 (es) |
| YU (1) | YU18897A (es) |
| ZA (1) | ZA974033B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5080759A1 (es) | 1996-05-15 | 2001-09-25 | Bayer Corp | Biarilacetilenos como inhibidores de la metaloproteasa de matriz |
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| FR2832925B1 (fr) * | 2001-12-03 | 2006-07-14 | Lipha | Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation |
| JP2012087113A (ja) * | 2010-09-22 | 2012-05-10 | Daicel Corp | フェニル酢酸化合物 |
| EP3126340A2 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
| CA2944614A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| WO2015150364A1 (de) * | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Substituierte benzotriazinonbutansäuren und ihre verwendung |
| US20170121315A1 (en) * | 2014-06-12 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE650081A (es) * | 1963-07-03 | |||
| FR2378741A1 (fr) * | 1977-02-01 | 1978-08-25 | Fabre Sa Pierre | Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques |
| JP2000502343A (ja) | 1995-12-22 | 2000-02-29 | ワーナー―ランバート・コンパニー | マトリックスメタロプロテイナーゼのインヒビターとしての芳香族ケト酸およびその誘導体 |
| TNSN97081A1 (fr) | 1996-05-15 | 2005-03-15 | Bayer Corp | Inhibition des matrices metalloproteinases par 2- (w-aroylkyl) -4-biaryl-4-des acides oxubutyriques |
-
1997
- 1997-05-09 ZA ZA9704033A patent/ZA974033B/xx unknown
- 1997-05-09 TN TNTNSN97086A patent/TNSN97086A1/fr unknown
- 1997-05-09 CO CO97025167A patent/CO5011113A1/es unknown
- 1997-05-09 HR HR970247A patent/HRP970247B1/xx not_active IP Right Cessation
- 1997-05-09 MY MYPI97002044A patent/MY116903A/en unknown
- 1997-05-12 YU YU18897A patent/YU18897A/sr unknown
- 1997-05-12 AT AT97923625T patent/ATE205822T1/de not_active IP Right Cessation
- 1997-05-12 DE DE69706874T patent/DE69706874T2/de not_active Expired - Fee Related
- 1997-05-12 CN CN97196458A patent/CN1225620A/zh active Pending
- 1997-05-12 PA PA19978429501A patent/PA8429501A1/es unknown
- 1997-05-12 ES ES97923625T patent/ES2160955T3/es not_active Expired - Lifetime
- 1997-05-12 WO PCT/US1997/007951 patent/WO1997043237A1/en not_active Ceased
- 1997-05-12 TW TW086106286A patent/TW442468B/zh not_active IP Right Cessation
- 1997-05-12 AU AU29389/97A patent/AU727468B2/en not_active Ceased
- 1997-05-12 JP JP54099297A patent/JP3354941B2/ja not_active Expired - Fee Related
- 1997-05-12 BR BR9709075A patent/BR9709075A/pt not_active Application Discontinuation
- 1997-05-12 AR ARP970101981A patent/AR007101A1/es unknown
- 1997-05-12 SV SV1997000033A patent/SV1997000033A/es unknown
- 1997-05-12 EP EP97923625A patent/EP0923529B1/en not_active Expired - Lifetime
- 1997-05-12 CA CA002253795A patent/CA2253795C/en not_active Expired - Fee Related
- 1997-05-14 ID IDP971604A patent/ID17326A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11510518A (ja) | 1999-09-14 |
| CO5011113A1 (es) | 2001-02-28 |
| SV1997000033A (es) | 1999-01-14 |
| ID17326A (id) | 1997-12-18 |
| PA8429501A1 (es) | 2000-05-24 |
| HRP970247A2 (en) | 1998-04-30 |
| YU18897A (en) | 1999-11-22 |
| DE69706874T2 (de) | 2002-03-28 |
| JP3354941B2 (ja) | 2002-12-09 |
| HRP970247B1 (en) | 2002-02-28 |
| WO1997043237A1 (en) | 1997-11-20 |
| ZA974033B (en) | 1998-02-19 |
| ATE205822T1 (de) | 2001-10-15 |
| EP0923529B1 (en) | 2001-09-19 |
| TNSN97086A1 (fr) | 2005-03-15 |
| AU727468B2 (en) | 2000-12-14 |
| AR007101A1 (es) | 1999-10-13 |
| TW442468B (en) | 2001-06-23 |
| AU2938997A (en) | 1997-12-05 |
| CA2253795A1 (en) | 1997-11-20 |
| CA2253795C (en) | 2002-10-15 |
| DE69706874D1 (en) | 2001-10-25 |
| MY116903A (en) | 2004-04-30 |
| BR9709075A (pt) | 1999-08-03 |
| EP0923529A1 (en) | 1999-06-23 |
| CN1225620A (zh) | 1999-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2139943T3 (es) | Nuevos inhibidores de la sintasa de prostaglandina. | |
| ES2100907T3 (es) | Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion. | |
| PT1229040E (pt) | Derivados nucleosido-monofosfato processo para a sua producao e sua utilizacao como farmacos imunossupressores | |
| AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
| ES2115096T3 (es) | Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. | |
| ES2094721T3 (es) | Analogos de la camptotecina solubles en agua. | |
| KR830006174A (ko) | 기관지 항경련성 화합물 제조방법 | |
| UY23657A1 (es) | Procedimiento para la preparacion de derivados de indol | |
| ES2081178T3 (es) | Compuestos anti-tumorales que contienen anillos quinazolina y tetrazol. | |
| EP0726267A4 (en) | QUINAZOLINE DERIVATIVE | |
| ES2160955T3 (es) | Derivados del acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz. | |
| ES2142763B1 (es) | Derivados de 5'-desoxicitidina. | |
| PT96030A (pt) | Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem | |
| MX9304424A (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| AR003137A1 (es) | Una composicion farmaceutica para tratar la leucemia | |
| PA8534001A1 (es) | Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos | |
| ES2133686T3 (es) | Nuevos derivados de benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ES2086090T3 (es) | Derivados de 4-pirimidinas, su preparacion y su aplicacion en terapeutica. | |
| ES2166838T3 (es) | 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas. | |
| MX9306178A (es) | Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion. | |
| ES2016017A6 (es) | Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico. | |
| ES2182086T3 (es) | Nuevos derivados de peptidil-arginina aldehido. | |
| ES2053780T3 (es) | Nuevos derivados 17-aza de 20,21-dinoreburnamenina y nuevos productos intermedios de preparacion, su aplicacion como medicamentos y composiciones que los contienen. | |
| ES8800904A1 (es) | Procedimiento para preparar derivados de 1,4-dihidropiridina con actividad cardiovascular | |
| PT91051A (pt) | Processo para a preparacao de novos derivados de glicerina e de composicoes farmaceuticas que os contem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 923529 Country of ref document: ES |